Your browser doesn't support javascript.
loading
Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients.
Ozen, Mehmet; Gunduz, Mehmet; Ates, Ozturk; Babacan, Taner; Sever, Ali R; Akin, Serkan; Ozisik, Yavuz; Altundag, Kadri.
Affiliation
  • Ozen M; Department of Hematology, Ankara University School of Medicine, Ankara, Turkey.
J BUON ; 21(4): 799-808, 2016.
Article in En | MEDLINE | ID: mdl-27685899
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptor, ErbB-2 / Lymph Nodes Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: J BUON Journal subject: NEOPLASIAS Year: 2016 Document type: Article Affiliation country: Turkey Country of publication: Cyprus
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptor, ErbB-2 / Lymph Nodes Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: J BUON Journal subject: NEOPLASIAS Year: 2016 Document type: Article Affiliation country: Turkey Country of publication: Cyprus